Abstract
Osteoarthritis of the knee (knee OA) is on the rise due to the aging population and increasing obesity. In addition to mechanical stress attributed to weight and age, osteoarthritis is associated with obesity and metabolic dysregulation. Here, a cross-sectional study targeting retrospectively registered 17,476 adults aged 50 years or older who were enrolled in the National Health and Nutrition Survey (2010–2011) was performed to analyze the association between the newly named metabolic associated fatty liver disease (MAFLD) and knee OA. Fatty liver index (FLI) ≥ 60 confirmed the presence of MAFLD, and FLI < 30 indicated the absence of MAFLD. Knee OA was diagnosed according to the Kellgren–Lawrence scale based on knee radiography results. A complex sample logistic regression analysis was performed. Statistically significant factors were adjusted to estimate probability ratios, and 95% confidence intervals were used to investigate the association between knee OA and MAFLD. The probability of knee OA was 1.479 times higher in the presence of MAFLD than that in the normal group. The results indicate that MAFLD is significantly associated with knee OA, suggesting that these two disorders should be managed simultaneously.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
22 March 2023
A Correction to this paper has been published: https://doi.org/10.1007/s10787-023-01184-2
References
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:1–7
Berenbaum F, Eymard F, Houard X (2013) Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol 25:114–118
BERENBAUM F (2013) Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cartil 21:16–21
Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47–S64
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology 55:2005–2023
Cho H, Kim Y-L, Jeong Y-J, Jung J (2018) Associations between osteoarthritis and metabolic syndrome in Korean adult: the 5th Korean national health and nutrition examination survey, 2010–2012. Korean Journal of Family Practice 8:292–298
Craig CL, Marshall AL, SJøSTRøM M, BAUMAN AE, BOOTH ML, AINSWORTH BE, PRATT M, EKELUND U, YNGVE A, SALLIS JF (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395
ENGSTRøM G, VERDIER MG, ROLLOF J, NILSSON P, LOHMANDER L (2009) C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthr Cartil 17:168–173
Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, Wong VW-S, Dufour J-F, Schattenberg J, Arrese M (2020) A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. https://doi.org/10.1016/j.jhep.2020.03.039
Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, YKI-JæRVINEN H (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999–2014
Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, Zheng M-H, Shiha G, Yilmaz Y, Gani R (2020) The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. https://doi.org/10.1007/s12072-020-10094-2
Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, Group LS (2014) Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40:1209–1222
Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D (2020) What’s in a name? Renaming ‘NAFLD’to ‘MAFLD.’ Liver Int 40:1254–1261
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922
Gastaldelli A, Kozakova M, HúJLUND K, FLYVBJERG A, FAVUZZI A, MITRAKOU A, BALKAU B, RISC INVESTIGATORS (2009) Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49:1537–1544
Griffin TM, Guilak F (2008) Why is obesity associated with osteoarthritis? Insights from mouse models of obesity. Biorheology 45:387–398
Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y (2015) Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine. https://doi.org/10.1097/MD.0000000000001682
Kellgren J, Lawrence J (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494
Khang AR, Lee HW, Yi D, Kang YH, Son SM (2019) The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea national health and nutrition examination survey 2010–2011. Diabetes Metab Syndr Obes 12:181
Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH (2012) Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:605–613
Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR (2015) Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause 22:1323
Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL (2013) External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 11:1201–1204
Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:686–690
Masuko K, Murata M, Suematsu N, Okamoto K, Yudoh K, Nakamura H, Kato T (2009) A metabolic aspect of osteoarthritis: lipid as a possible contributor to the pathogenesis of cartilage degradation. Clin Exp Rheumatol 27:347
Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, Abedi K, Aghapour S, Fallahnezhad M (2016) Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol 22:3023
Niu J, Clancy M, Aliabadi P, Vasan R, Felson DT (2017) Metabolic syndrome, its components, and knee osteoarthritis: the Framingham osteoarthritis Study. Arthritis Rheumatol 69:1194–1203
SELLAM (2013) Osteoarthritis as a disease of mechanics. Osteoarthr Cartil 21:10–15
Sviklāne L, Olmane E, Dzērve Z, Kupčs K, Pīrāgs V, Sokolovska J (2018) Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol 33:270–276
Thijssen E, van Caam A, van der Kraan PM (2015) Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. Rheumatology 54:588–600
Valenti L, Pelusi S (2020) Redefining fatty liver disease classification in 2020. Liver Int. https://doi.org/10.1111/liv.14430
Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2011) Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in Japanese men and women: the ROAD study. J Rheumatol 38:921–930
Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E (2013) Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 19:57
Zhuo Q, Yang W, Chen J, Wang Y (2012) Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 8:729
Funding
No funding was received.
Author information
Authors and Affiliations
Contributions
ALH: Study design, data collection, data analysis, and manuscript drafting.
Corresponding author
Ethics declarations
Conflict of interests
The author declares no competing interests.
Ethical approval
This study followed the ethical standards laid out in the Declaration of Helsinki. The study was approved by the Clinical Trial Screening Committee of Wonkwang University Hospital (institutional review board [IRB] approval number: 2021-03-032). The name of the IRB is Wonkwang University Hospital Institutional Review Board, which belongs to Wonkwang University 3rd General Hospital, and its address is as follows: Wonkwang University Hospital, Sinyong-dong 344-2, Iksan, Jeollabuk-do.
Consent to participate
Not applicable. The data used were publicly available at the national level, and anonymity was guaranteed. The author also declared that the data will not be used for any purpose other than the research purpose.
Consent for publication
Not applicable. This is because all patient information was investigated anonymously, and the manuscript did not reveal the patient's personal clinical information or the patient's image.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Han, A.L. Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES). Inflammopharmacol 29, 1111–1118 (2021). https://doi.org/10.1007/s10787-021-00842-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-021-00842-7